IMNN: חוב להון עצמי Imunon Inc

This chart illustrates that the market valuation of the total debt-to-equity ratio for Imunon, Inc. (IMNN) is 1.97. The business focuses on developing DNA cancer therapies, leveraging the results of the OVATION project and the potential of the PlaCCine platform. High physician authority is driven by the reliability of gene delivery methods, while the absence of external political risks and US localization ensure the stability of operational processes.

For Imunon, Inc. (IMNN), which ensures nucleotide supply chain redundancy to maintain clinical trial continuity, the debt-to-equity ratio trend reflects the stability of its operational financing. This ratio compares total liabilities to equity, determining the business's level of dependence on borrowed resources: low values minimize bankruptcy risk, whereas a high debt load may constrain growth rates.